Life
Briefing: Trump's Drug Pricing Moves and GSK Asthma Drug Insights
Strategic angle: The White House intensifies pressure on Congress for drug pricing legislation.
Editorial Staff
1 min read
Updated about 1 month ago
On March 17, 2026, the White House announced an intensified campaign aimed at Congress to pass legislation that would establish a 'most-favored nation' drug pricing policy.
This policy aims to ensure that the prices paid for drugs by the U.S. are not higher than those paid by other countries, potentially altering the pricing dynamics within the pharmaceutical industry.
In parallel, developments regarding GSK's new asthma drug are being monitored, as they may also be influenced by these legislative changes and the broader drug pricing landscape.